Progenics Pharmaceuticals to Present at the BIO International Convention

| Source: Progenics Pharmaceuticals Inc.

TARRYTOWN, N.Y., June 15, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will present at the 2012 BIO International Convention's Business Forum, a unique venue where biotechnology companies, academic research institutions and investors intersect to review strategic opportunities. Mr. Baker will give a corporate overview on Monday, June 18 at 1:45 PM ET in the Boston Convention & Exhibition Center, Boston, MA.

About Progenics

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company dedicated to developing innovative medicines to treat disease, with a focus on cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, Relistor®, to Salix Pharmaceuticals for markets worldwide other than Japan, where Ono Pharmaceutical holds an exclusive license for the subcutaneous formulation. Relistor (methylnaltrexone bromide) subcutaneous injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of Relistor by patients with chronic, non-cancer pain. For more information, please visit

The Progenics Pharmaceuticals Inc. logo is available at

Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this announcement.


Amy Martini
Corporate Affairs
(914) 789-2816